Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · inactive EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events 12 to 50 weeks compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Biologics showed no clear difference in withdrawals due to adverse events 12 to 44 weeks compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with painful diabetic neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Investigator‐assessed adverse events (short‐term) · people with acne scars
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
It is very uncertain whether four‐food elimination diet with omeprazole changes withdrawals due to adverse events at 8 to 12 weeks compared with omeprazole (very low certainty).
1 finding from 1 review
Participants with one or more serious adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in participants with one or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Postoperative complications (infection) / adverse events · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…
1 finding from 1 review
Withdrawals due to adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects (tooth staining and other side effects) · Children and adults with active dental caries (aged 1-50; mostly preschool/school children with primary dentition)
SDF commonly causes black staining of arrested lesions; only mild, transient adverse events were reported, with no major adverse events (ungraded).
1 finding from 1 review
Any adverse events with use of FMT for induction of remission in CD · Patients with active Crohn's disease
1 finding from 1 review
Serious adverse events with use of FMT for induction of remission in CD · Patients with active Crohn's disease
1 finding from 1 review
Number of women with adverse events (vaginal bleeding, voiding difficulty) · pelvic organ prolapse in women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).
1 finding from 1 review
Proportion of participants with vision‐threatening adverse events (RR < 1 favored) · Adults with refractive errors
1 finding from 1 review
no estimate extracted
4 participants
Very low